Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuo Ma

Showing results (201-210 of 253) with videos related to

Pageof 26
Sort By:
Leukemia & Lymphoma|January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapiesEli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Journal of Ethnopharmacology|September 22, 2018
Comparative comprehension on the anti-rheumatic Chinese herbal medicine Siegesbeckiae Herba: Combined computational predictions and experimental investigationsQian Ru Zhang, Zhang Feng Zhong, Wei Sang, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Oncogene|April 3, 2025
Phosphorylation enhanced OTUD3 deubiquitination ARID3A promotes the progress of cholangiocarcinomaDeng-Yong Zhang, Yan Zhu, Shuo-Shuo Ma, et al.
Journal of Pharmaceutical Analysis|April 15, 2024
Small molecule deoxynyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapyKe-Gang Linghu, Tian Zhang, Guang-Tao Zhang, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
NPJ Digital Medicine|January 26, 2026
Multimodal digital biopsy for preoperative prediction of occult peritoneal metastasis in gastric cancerSheng Chen, Ping'an Ding, Yihao Yang, et al.
Blood|February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaAriela Noy, Sven de Vos, Catherine Thieblemont, et al.
Pageof 26

Showing results (201-210 of 253) with videos related to

Sort By:
Pageof 26
Leukemia & Lymphoma|January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapiesEli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Journal of Ethnopharmacology|September 22, 2018
Comparative comprehension on the anti-rheumatic Chinese herbal medicine Siegesbeckiae Herba: Combined computational predictions and experimental investigationsQian Ru Zhang, Zhang Feng Zhong, Wei Sang, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Oncogene|April 3, 2025
Phosphorylation enhanced OTUD3 deubiquitination ARID3A promotes the progress of cholangiocarcinomaDeng-Yong Zhang, Yan Zhu, Shuo-Shuo Ma, et al.
Journal of Pharmaceutical Analysis|April 15, 2024
Small molecule deoxynyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapyKe-Gang Linghu, Tian Zhang, Guang-Tao Zhang, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
NPJ Digital Medicine|January 26, 2026
Multimodal digital biopsy for preoperative prediction of occult peritoneal metastasis in gastric cancerSheng Chen, Ping'an Ding, Yihao Yang, et al.
Blood|February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaAriela Noy, Sven de Vos, Catherine Thieblemont, et al.
Pageof 26